ALX-0171: Phase I data

An open-label, Belgian Phase I trial in 41 healthy volunteers showed that once-daily 200 mg inhaled ALX-0171 for 5 consecutive days led to "rapid attainment of clinically relevant [ALX-0171] levels." ...